We are live on ! Find out more
ERNA icon

Eterna Therapeutics

44 hedge funds and large institutions have $47.3M invested in Eterna Therapeutics in 2021 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 4

38% more funds holding

Funds holding: 3244 (+12)

17% more call options, than puts

Call options by funds: $3.21M | Put options by funds: $2.75M

13% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 8

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% less ownership

Funds ownership: 0%0% (-0%)

40% less capital invested

Capital invested by funds: $78.3M → $47.3M (-$31M)

Holders
44
Holders Change
+12
Holders Change %
+37.5%
% of All Funds
0.77%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
16
Increased
9
Reduced
8
Closed
4
Calls
$3.21M
Puts
$2.75M
Net Calls
+$456K
Net Calls Change
+$5.78M

ERNA Hedge Fund Activity: Q3 2021 in Review

44 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Eterna Therapeutics (ERNA) for Q3 2021, worth a combined $47.3M — down 40% from $78.3M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new ERNA positions and 4 closed out — a net gain of 12 holders — while 9 added to existing stakes and 8 trimmed.

The largest buyer was BlackRock, adding an estimated $4.4M. The largest seller was Nuveen, cutting an estimated $1.99M.

  • 44 institutional investors held Eterna Therapeutics (ERNA) as of Q3 2021, up from 32 in Q2 2021.
  • Funds reported $47.3M of Eterna Therapeutics stock for Q3 2021, down 40% quarter-over-quarter.
  • 16 funds opened new Eterna Therapeutics positions in Q3 2021 and 4 closed out, a net change of +12 holders.
  • The largest Eterna Therapeutics buyer in Q3 2021 was BlackRock, an estimated $4.4M added.
  • The largest Eterna Therapeutics seller in Q3 2021 was Nuveen, an estimated $1.99M sold.

Based on aggregated 13F filings for Q3 2021.